Drug Type Chemical drugs |
Synonyms |
Target |
Action agonists |
Mechanism GHR agonists(Growth hormone receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC78H123N23O23S2 |
InChIKeyGVIYUKXRXPXMQM-BPXGDYAESA-N |
CAS Registry221231-10-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute migraine | Phase 2 | Australia | 24 Sep 2019 | |
Diabetic peripheral neuropathy | Phase 2 | Australia | 09 Apr 2019 | |
Diabetic peripheral neuropathy | Phase 2 | United Kingdom | 09 Apr 2019 | |
Neuralgia, Postherpetic | Phase 2 | United Kingdom | 09 Apr 2019 | |
Neuralgia, Postherpetic | Phase 2 | Australia | 09 Apr 2019 | |
Obesity | Phase 2 | Australia | - | |
Osteoporosis | Phase 2 | Australia | - | - |
Lumbar Radiculopathy | Phase 1 | Australia | 17 May 2022 | |
Radicular Pain | Phase 1 | Australia | 17 May 2022 |
Phase 2 | 53 | (LAT8881) | gogzxrdenc(znoryuphdd) = uapbxqnpkv hpthuxpszp (blycxgczfl, qtnugvfmfr - xoyapmzacz) View more | - | 23 Apr 2021 | ||
Placebo (Placebo) | gogzxrdenc(znoryuphdd) = wwhjgghgph hpthuxpszp (blycxgczfl, sjwbfxexsm - hzbeibbfkq) View more | ||||||
Phase 2 | 21 | (Active) | dvkvycevqo(hnrmpxesqn) = prtheqlhqf wutfghfqkt (pvrvgpqorr, ldigfeoieq - ttsaodhifc) View more | - | 30 Mar 2021 | ||
Placebo (Placebo) | dvkvycevqo(hnrmpxesqn) = ihaqntnoxx wutfghfqkt (pvrvgpqorr, hiuxdugjda - osslsjbvym) View more |